Moderate riskFDA DrugClass III

Chiesi Revcovi injection recalled for failed stability specifications

Chiesi USA, Inc. is recalling Revcovi (elapegademase-lvlr) Injection due to out-of-specification stability results in the protein concentration profile. The affected lot was distributed to Missouri and Tennessee. No injuries have been reported.

From the FDA notice · Read the official notice ↗ · All Chiesi recalls

What to do

  1. If you have a vial from lot #1221973 (expiration 3/24/2027), contact your healthcare provider or pharmacist immediately.
  2. Do not use the recalled medication without consulting your healthcare provider.
  3. Return the medication to your pharmacy for proper handling.

Is yours affected?

Compare your label or packaging with the recalled product.

Product
Revcovi (elapegademase-lvlr) Injection, 2.4mg/1.5mL (1.6 mg/mL), Single-Dose Vial, Rx Only, For Intramuscular Use Only, Mfd. by Chiesi USA, Inc., Cary, NC 27518, NDC 10122-502-01
Sold in
MO, TN
Made for
All ages (0 months and older)

Details

Units affected
3,002 vials
Illnesses reported
None reported
Manufactured in
175 Regency Woods Pl Ste 600, N/A, Cary, NC, United States
Classification
Class III
Recall number
D-0838-2026

In the FDA's words

Description
Revcovi (elapegademase-lvlr) Injection, 2.4mg/1.5mL (1.6 mg/mL), Single-Dose Vial, Rx Only, For Intramuscular Use Only, Mfd. by Chiesi USA, Inc., Cary, NC 27518, NDC 10122-502-01 Failed Stability Specifications: Out of specification stability result for the protein concentration profile. Lot#: 1221973, Exp 3/24/2027 Distribution: MO, TN Affected quantity: 3,002 vials
Hazard
Failed Stability Specifications: Out of specification stability result for the protein concentration profile.

Related topics